By Fineline Cube The National Medical Products Administration (NMPA) has released its National Drug Sampling Inspection Annual Report (2025), revealing that 99.5% of tested pharmaceutical batches met quality specifications, reinforcing confidence in China’s drug safety standards.
Regulatory Overview & Key Metrics
| Metric | Value |
|---|---|
| Total Samples Tested | 16,925 batches |
| Drug Varieties Evaluated | 125 |
| Compliant Batches | 16,842 (99.5%) |
| Non-Compliant Batches | 83 (0.5%) |
| Products with 100% Compliance | 104 |
Product Categories with Full Compliance
| Category | Products | Batches Tested |
|---|---|---|
| Chemical Drugs | 59 | 8,077 |
| Traditional Chinese Medicine | 40 | 5,640 |
| Biological Products | 5 | 180 |
| Total | 104 | 13,897 |
Problem-Oriented Testing Methodology
The NMPA employs a targeted, risk-based approach to select products for national sampling, prioritizing:
- High-utilization therapeutics with broad clinical application
- Products with elevated adverse event reports or frequent consumer complaints
- Drugs flagged during routine supervision for potential quality/safety concerns
- Therapies requiring urgent re-evaluation following significant quality standard upgrades
- Items suspected of adulteration, falsification, or other regulatory violations
This strategic methodology ensures efficient allocation of regulatory resources while maintaining comprehensive market oversight.
Expert-Driven Evaluation Process
Prior to finalizing the annual testing list, the NMPA:
- Solicits input from relevant units across China’s drug regulatory system
- Convenes multidisciplinary expert panels (regulatory, testing, clinical specialists)
- Conducts rigorous evaluations to determine the final product selection
“The testing and research results indicate that the quality of drugs in China remains consistently high,” the report concluded, underscoring the effectiveness of the nation’s pharmaceutical quality control framework.
Forward-Looking Statements
This brief reflects current regulatory findings and methodologies. Future inspection outcomes may vary based on evolving market dynamics, emerging quality risks, and policy adjustments within China’s pharmaceutical regulatory landscape.-Fineline Info & Tech